Microinjection of sanguinarine into the ventrolateral orbital cortex inhibits Mkp-1 and exerts an antidepressant-like effect in rats

Neuroscience Letters

Volumn 506, Issue 2, 2012, Pages 327-331

  Chen, Yunchun ^a   Wang, Huaning ^a   Zhang, Ruiguo ^a   Wang, Huaihai ^a   Peng, Zhengwu ^a   Sun, Runzhu ^a   Tan, Qingrong ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Antidepression; Microinjection; Mkp 1; Sanguinarine; Ventrolateral orbital cortex

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; SANGUINARINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENCY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FORCED SWIMMING TEST; IMMOBILIZATION; IMMUNOBLOTTING; MALE; MICROINJECTION; NONHUMAN; ORBITAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SYSTEMIC THERAPY; VENTROLATERAL ORBITAL CORTEX;

ANIMALS; ANTIDEPRESSIVE AGENTS; BENZOPHENANTHRIDINES; BLOTTING, WESTERN; CEREBRAL CORTEX; DEPRESSION; DISEASE MODELS, ANIMAL; DUAL SPECIFICITY PHOSPHATASE 1; INJECTIONS, INTRAVENTRICULAR; ISOQUINOLINES; MALE; MICROINJECTIONS; PROTEIN KINASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84655167683     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2011.11.038     Document Type: Article

References (30)

1. Adhami V.M., Aziz M.H., Mukhtar H., Ahmad N. Activation of prodeath Bcl-2 family proteins and mitochondrial apoptosis pathway by sanguinarine in immortalized human HaCaT keratinocytes. Clin. Cancer Res. 2003, 9:3176-3182.
2. Agid Y., Buzsaki G., Diamond D.M., Frackowiak R., Giedd J., Girault J.A., Grace A., Lambert J.J., Manji H., Mayberg H., Popoli M., Prochiantz A., Richter-Levin G., Somogyi P., Spedding M., Svenningsson P., Weinberger D. Viewpoint - how can drug discovery for psychiatric disorders be improved?. Nat. Rev. Drug Discov. 2007, 6:189-201.
3. Brondello J.M., Brunet A., Pouyssegur J., McKenzie F.R. The dual specificity mitogen-activated protein kinase phosphatase-1 and -2 are induced by the p42/p44 MAPK cascade. J. Biol. Chem. 1997, 272:1368-1376.
4. Chaturvedi M.M., Kumar A., Darnay B.G., Chainy G.B., Agarwal S., Aggarwal B.B. Sanguinarine (pseudochelerythrine) is a potent inhibitor of NF-kappaB activation, IkappaBalpha phosphorylation, and degradation. J. Biol. Chem. 1997, 272:30129-30134.
5. Cryan J.F., Markou A., Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol. Sci. 2002, 23:238-245.
6. Cryan J.F., Valentino R.J., Lucki I. Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci. Biobehav. Rev. 2005, 29:547-569.
7. Dichter G.S., Felder J.N., Smoski M.J. The effects of Brief Behavioral Activation Therapy for Depression on cognitive control in affective contexts: an fMRI investigation. J. Affect. Disord. 2010, 126:236-244.
8. Duman C.H., Schlesinger L., Kodama M., Russell D.S., Duman R.S. A role for MAP kinase signaling in behavioral models of depression and antidepressant treatment. Biol. Psychiatry 2007, 61:661-670.
9. Duric V., Banasr M., Licznerski P., Schmidt H.D., Stockmeier C.A., Simen A.A., Newton S.S., Duman R.S. A negative regulator of MAP kinase causes depressive behavior. Nat. Med. 2010, 16:1328-1332.
10. Dwivedi Y., Rizavi H.S., Roberts R.C., Conley R.C., Tamminga C.A., Pandey G.N. Reduced activation and expression of ERK1/2 MAP kinase in the post-mortem brain of depressed suicide subjects. J. Neurochem. 2001, 77:916-928.
11. El Khoury A., Gruber S.H., Mork A., Mathe A.A. Adult life behavioral consequences of early maternal separation are alleviated by escitalopram treatment in a rat model of depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006, 30:535-540.
12. Hendrie C.A., Pickles A.R. Depression as an evolutionary adaptation: implications for the development of preclinical models. Med. Hypotheses 2009, 72:342-347.
13. Huang T.Y., Lin C.H. Role of amygdala MAPK activation on immobility behavior of forced swim rats. Behav. Brain Res. 2006, 173:104-111.
14. Jeffrey K.L., Camps M., Rommel C., Mackay C.R. Targeting dual-specificity phosphatases: manipulating MAP kinase signalling and immune responses. Nat. Rev. Drug Discov. 2007, 6:391-403.
15. Kolb B., Pellis S., Robinson T.E. Plasticity and functions of the orbital frontal cortex. Brain Cogn. 2004, 55:104-115.
16. Malikova J., Zdarilova A., Hlobilkova A., Ulrichova J. The effect of chelerythrine on cell growth, apoptosis, and cell cycle in human normal and cancer cells in comparison with sanguinarine. Cell Biol. Toxicol. 2006, 22:439-453.
17. Mann J.J., Huang J.Y., Underwood M.D., Kassir S.A., Oppenheim S., Kelly T.M., Dwork A.J., Arango V. A serotonin transporter gene promoter polymorphism (5-HTTLPR) and prefrontal cortical finding in major depression and suicide. Arch. Gen. Psychiatry 2000, 57:729-738.
18. Paxinos G., Watson C. The Rat Brain, in Stereotaxic Coordinates 2005, Sydney, Elsevier Academic Press. 2nd ed.
19. Porsolt R.D., Le Pichon M., Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977, 266:730-732.
20. Qi X., Lin W., Li J., Pan Y., Wang W. The depressive-like behaviors are correlated with decreased phosphorylation of mitogen-activated protein kinases in rat brain following chronic forced swim stress. Behav. Brain Res. 2006, 175:233-240.
21. Qi X., Lin W., Li J., Li H., Wang W., Wang D., Sun M. Fluoxetine increases the activity of the ERK-CREB signal system and alleviates the depressive-like behavior in rats exposed to chronic forced swim stress. Neurobiol. Dis. 2008, 31:278-285.
22. Sheline Y.I. Neuroimaging studies of mood disorder effects on the brain. Biol. Psychiatry 2003, 54:338-352.
23. Shirayama Y., Chen A.C., Nakagawa S., Russell D.S., Duman R.S. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J. Neurosci. 2002, 22:3251-3261.
24. Takaki M., Ujike H., Kodama M., Takehisa Y., Nakata K., Kuroda S. Two kinds of mitogen-activated protein kinase phosphatases, MKP-1 and MKP-3, are differentially activated by acute and chronic methamphetamine treatment in the rat brain. J. Neurochem. 2001, 79:679-688.
25. 2-deficient mice. Neuropsychopharmacology 2009, 34:1416-1426.
26. Ujike H., Takaki M., Kodama M., Kuroda S. Gene expression related to synaptogenesis, neuritogenesis, and MAP kinase in behavioral sensitization to psychostimulants. Ann. N. Y. Acad. Sci. 2002, 965:55-67.
27. Ustun T.B. The worldwide burden of depression in the 21st century. Treatment of Depression: Bridging the 21st Century 2001, pp. 35-45.
28. Vogt A., Tamewitz A., Skoko J., Sikorski R.P., Giuliano K.A., Lazo J.S. The benzo[c] phenanthridine alkaloid, sanguinarine, is a selective, cell-active inhibitor of mitogen-activated protein kinase phosphatase-1. J. Biol. Chem. 2005, 280:19078-19086.
29. Xing B., Zhao Y., Zhang H., Dang Y.H., Chen T., Huang J.F., Luo Q. Microinjection of valproic acid into the ventrolateral orbital cortex exerts an antidepressant-like effect in the rat forced swim test. Brain Res. Bull. 2011, 85:153-157.
30. Zhang Y., Kudo T., Ku Y., Zhao F., Kano M., Shimizu Y., Hayashi H., Hamada T., Kanetaka H. The role of extracellular signal-regulated kinase 5 signaling pathway in neurons. Interface Oral Health Sci. 2010, 2009:199-201.